Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial
September 20, 2018 08:00 ET
|
Galectin Therapeutics Inc.
Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). The published response rate of KEYTRUDA alone is 33%...
Galectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
August 28, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update
August 14, 2018 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
June 27, 2018 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Inc. Announces New CEO
June 12, 2018 08:32 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 12, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H....
Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board
June 04, 2018 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors...
Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
May 14, 2018 09:05 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with...
Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update
May 11, 2018 16:10 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 11, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
April 18, 2018 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
April 04, 2018 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the presentation of a...